Abstract

The objective of this retrospective study (N = 169) was to compare the overall survival (OS) of different subtypes of mantle cell lymphoma (MCL) treated by the Nebraska Lymphoma Study Group between 1984 and 2012. The overall response rate to various therapies including stem cell transplant (SCT) was similar (p = 0.44) between blastoid, diffuse and nodular subtypes. At 5 years, blastoid and diffuse subtypes had worse OS (overall p = 0.005) compared to nodular subtype. In multivariate analysis, the blastoid and diffuse subtypes had similar risk of death (p = 0.14) whereas the nodular subtype had a lower risk compared to blastoid (HR 0.48, 95% CI 0.27-0.87, p = 0.01). The use of SCT was associated with lower risk of death. In univariate analysis, blastoid subtype had better OS with intensive upfront therapy. In conclusion, the OS of blastoid subtype is worse than nodular MCL but may improve with the use of SCT and probably intensive induction therapy.

Original languageEnglish (US)
Pages (from-to)1327-1334
Number of pages8
JournalLeukemia and Lymphoma
Volume57
Issue number6
DOIs
StatePublished - Jun 2 2016

Fingerprint

Mantle-Cell Lymphoma
Lymphoma
Stem Cells
Transplants
Follicular Lymphoma
Therapeutics
Multivariate Analysis
Retrospective Studies

Keywords

  • Blastoid variant
  • diffuse subtype
  • intensive induction therapy
  • mantle cell lymphoma
  • nodular subtype
  • stem cell transplantation

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

@article{8d80df2696ee464683e95b561a9ba359,
title = "Clinicopathologic features, management and outcomes of blastoid variant of mantle cell lymphoma: A Nebraska Lymphoma Study Group Experience",
abstract = "The objective of this retrospective study (N = 169) was to compare the overall survival (OS) of different subtypes of mantle cell lymphoma (MCL) treated by the Nebraska Lymphoma Study Group between 1984 and 2012. The overall response rate to various therapies including stem cell transplant (SCT) was similar (p = 0.44) between blastoid, diffuse and nodular subtypes. At 5 years, blastoid and diffuse subtypes had worse OS (overall p = 0.005) compared to nodular subtype. In multivariate analysis, the blastoid and diffuse subtypes had similar risk of death (p = 0.14) whereas the nodular subtype had a lower risk compared to blastoid (HR 0.48, 95{\%} CI 0.27-0.87, p = 0.01). The use of SCT was associated with lower risk of death. In univariate analysis, blastoid subtype had better OS with intensive upfront therapy. In conclusion, the OS of blastoid subtype is worse than nodular MCL but may improve with the use of SCT and probably intensive induction therapy.",
keywords = "Blastoid variant, diffuse subtype, intensive induction therapy, mantle cell lymphoma, nodular subtype, stem cell transplantation",
author = "Bhatt, {Vijaya R} and Loberiza, {Fausto R.} and Smith, {Lynette M} and Armitage, {James Olen} and Greiner, {Timothy Charles} and Martin Bast and Lunning, {Matthew A} and Bierman, {Philip Jay} and Vose, {Julie Marie} and Bociek, {Robert G}",
year = "2016",
month = "6",
day = "2",
doi = "10.3109/10428194.2015.1094801",
language = "English (US)",
volume = "57",
pages = "1327--1334",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Clinicopathologic features, management and outcomes of blastoid variant of mantle cell lymphoma

T2 - A Nebraska Lymphoma Study Group Experience

AU - Bhatt, Vijaya R

AU - Loberiza, Fausto R.

AU - Smith, Lynette M

AU - Armitage, James Olen

AU - Greiner, Timothy Charles

AU - Bast, Martin

AU - Lunning, Matthew A

AU - Bierman, Philip Jay

AU - Vose, Julie Marie

AU - Bociek, Robert G

PY - 2016/6/2

Y1 - 2016/6/2

N2 - The objective of this retrospective study (N = 169) was to compare the overall survival (OS) of different subtypes of mantle cell lymphoma (MCL) treated by the Nebraska Lymphoma Study Group between 1984 and 2012. The overall response rate to various therapies including stem cell transplant (SCT) was similar (p = 0.44) between blastoid, diffuse and nodular subtypes. At 5 years, blastoid and diffuse subtypes had worse OS (overall p = 0.005) compared to nodular subtype. In multivariate analysis, the blastoid and diffuse subtypes had similar risk of death (p = 0.14) whereas the nodular subtype had a lower risk compared to blastoid (HR 0.48, 95% CI 0.27-0.87, p = 0.01). The use of SCT was associated with lower risk of death. In univariate analysis, blastoid subtype had better OS with intensive upfront therapy. In conclusion, the OS of blastoid subtype is worse than nodular MCL but may improve with the use of SCT and probably intensive induction therapy.

AB - The objective of this retrospective study (N = 169) was to compare the overall survival (OS) of different subtypes of mantle cell lymphoma (MCL) treated by the Nebraska Lymphoma Study Group between 1984 and 2012. The overall response rate to various therapies including stem cell transplant (SCT) was similar (p = 0.44) between blastoid, diffuse and nodular subtypes. At 5 years, blastoid and diffuse subtypes had worse OS (overall p = 0.005) compared to nodular subtype. In multivariate analysis, the blastoid and diffuse subtypes had similar risk of death (p = 0.14) whereas the nodular subtype had a lower risk compared to blastoid (HR 0.48, 95% CI 0.27-0.87, p = 0.01). The use of SCT was associated with lower risk of death. In univariate analysis, blastoid subtype had better OS with intensive upfront therapy. In conclusion, the OS of blastoid subtype is worse than nodular MCL but may improve with the use of SCT and probably intensive induction therapy.

KW - Blastoid variant

KW - diffuse subtype

KW - intensive induction therapy

KW - mantle cell lymphoma

KW - nodular subtype

KW - stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=84945207628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945207628&partnerID=8YFLogxK

U2 - 10.3109/10428194.2015.1094801

DO - 10.3109/10428194.2015.1094801

M3 - Article

C2 - 26377137

AN - SCOPUS:84945207628

VL - 57

SP - 1327

EP - 1334

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 6

ER -